131 Downloads (Pure)

Abstract

Disclosed herein are cationic liposomes suitable for specific delivery of immunomodulating agents to monocytes and dendritic cells. The cationic liposomes comprise phospholipids, cholesterol, cationic lipids, PEG and at least one active ingredient and have a zeta potential in the range of 13-25 mV. Further disclosed are uses of such cationic liposomes in various pharmaceutical applications.
Original languageEnglish
IPCA61K31/522; A61K39/39; A61K47/02; A61K47/69; A61K9/127; A61P35/00
Patent numberWO2019012107
Filing date17/01/2019
CountryInternational Bureau of the World Intellectual Property Organization (WIPO)
Priority date13/07/2017
Priority numberEP20170181122
Publication statusPublished - 2019

Cite this

Andresen, T. L., Jensen, S. S., Henriksen, J. R., Parhamifar, L., & Lassen, R. M. M. (2019). IPC No. A61K31/522; A61K39/39; A61K47/02; A61K47/69; A61K9/127; A61P35/00. Cationic liposomes. (Patent No. WO2019012107 ).
Andresen, Thomas Lars (Inventor) ; Jensen, Simon Skjøde (Inventor) ; Henriksen, Jonas Rosager (Inventor) ; Parhamifar, Ladan (Inventor) ; Lassen, Rasmus Mikkel Münter (Inventor). / Cationic liposomes. IPC No.: A61K31/522; A61K39/39; A61K47/02; A61K47/69; A61K9/127; A61P35/00. Patent No.: WO2019012107 . Jan 17, 2019.
@misc{730c8e1ed00d4e5497a8aacf5ae89910,
title = "Cationic liposomes",
abstract = "Disclosed herein are cationic liposomes suitable for specific delivery of immunomodulating agents to monocytes and dendritic cells. The cationic liposomes comprise phospholipids, cholesterol, cationic lipids, PEG and at least one active ingredient and have a zeta potential in the range of 13-25 mV. Further disclosed are uses of such cationic liposomes in various pharmaceutical applications.",
author = "Andresen, {Thomas Lars} and Jensen, {Simon Skj{\o}de} and Henriksen, {Jonas Rosager} and Ladan Parhamifar and Lassen, {Rasmus Mikkel M{\"u}nter}",
year = "2019",
language = "English",
type = "Patent",
note = "WO2019012107 ; A61K31/522; A61K39/39; A61K47/02; A61K47/69; A61K9/127; A61P35/00",

}

Andresen, TL, Jensen, SS, Henriksen, JR, Parhamifar, L & Lassen, RMM Jan. 17 2019, Cationic liposomes, Patent No. WO2019012107 , IPC No. A61K31/522; A61K39/39; A61K47/02; A61K47/69; A61K9/127; A61P35/00.

Cationic liposomes. / Andresen, Thomas Lars (Inventor); Jensen, Simon Skjøde (Inventor); Henriksen, Jonas Rosager (Inventor); Parhamifar, Ladan (Inventor); Lassen, Rasmus Mikkel Münter (Inventor).

IPC No.: A61K31/522; A61K39/39; A61K47/02; A61K47/69; A61K9/127; A61P35/00. Patent No.: WO2019012107 . Jan 17, 2019.

Research output: Patent

TY - PAT

T1 - Cationic liposomes

AU - Andresen, Thomas Lars

AU - Jensen, Simon Skjøde

AU - Henriksen, Jonas Rosager

AU - Parhamifar, Ladan

AU - Lassen, Rasmus Mikkel Münter

PY - 2019

Y1 - 2019

N2 - Disclosed herein are cationic liposomes suitable for specific delivery of immunomodulating agents to monocytes and dendritic cells. The cationic liposomes comprise phospholipids, cholesterol, cationic lipids, PEG and at least one active ingredient and have a zeta potential in the range of 13-25 mV. Further disclosed are uses of such cationic liposomes in various pharmaceutical applications.

AB - Disclosed herein are cationic liposomes suitable for specific delivery of immunomodulating agents to monocytes and dendritic cells. The cationic liposomes comprise phospholipids, cholesterol, cationic lipids, PEG and at least one active ingredient and have a zeta potential in the range of 13-25 mV. Further disclosed are uses of such cationic liposomes in various pharmaceutical applications.

M3 - Patent

M1 - WO2019012107

Y2 - 2019/01/17

ER -

Andresen TL, Jensen SS, Henriksen JR, Parhamifar L, Lassen RMM, inventors. Cationic liposomes. A61K31/522; A61K39/39; A61K47/02; A61K47/69; A61K9/127; A61P35/00. 2019.